<DOC>
	<DOCNO>NCT01108705</DOCNO>
	<brief_summary>The purpose study determine whether brivanib effective treatment liver cancer Asian patient fail could tolerate sorafenib therapy .</brief_summary>
	<brief_title>Comparison Brivanib Best Supportive Care ( BSC ) With Placebo BSC Treatment Liver Cancer Asian Patients Who Have Failed Sorafenib Treatment</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Carcinoma , Hepatocellular</mesh_term>
	<mesh_term>Sorafenib</mesh_term>
	<criteria>Key Diagnosis advance hepatocellular carcinoma Asian ethnicity Patient fail â‰¥14 day sorafenib treatment Cirrhotic status ChildPugh Class A B score 7 Eastern Cooperative Oncology Group performance status 0 , 1 , 2 Life expectancy least 8 week Adequate hematologic , hepatic , renal function Key Women childbearing potential unwilling unable use acceptable method avoid pregnancy Previous concurrent cancer distinct primary site History active cardiac disease Thrombotic embolic event within past 6 month Inability swallow tablet untreated malabsorption syndrome History HIV infection Prior use systemic investigational agent hepatocellular carcinoma ( except sorafenib )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2015</verification_date>
</DOC>